Recombinant WT1 antigen-specific cancer immunotherapeutic
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Recombinant WT1 antigen-specific cancer immunotherapeutic, covering 2012-01-20 to 2012-01-20. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia [Phase 1, Phase 2]